Davis Maris News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi made an overture, and have astrazeneca, celgene and gilead, but it was pfizers 14 billion that won out. Sending shares up almost 20 . Shares of pfizer fell slightly. Meg tirrell tells us why medivation was so sought after. Reporter a 14 billion deal phaser beat our rivals to win in an allcash deal that capped a monthlong process. With it pfizer gained the Prostate Cancer drug this draws more than 2 billion in retch, proceeds that are split with the partner. And it gains two experimental drugs for cancer, building up a growing fo global spending on cancer medicines reached 107 billion la...

Sanofi made an overture, and have astrazeneca, celgene and gilead, but it was pfizers 14 billion that won out. Sending shares up almost 20 . Shares of pfizer fell slightly. Meg tirrell tells us why medivation was so sought after. Reporter a 14 billion deal phaser beat our rivals to win in an allcash deal that capped a monthlong process. With it pfizer gained the Prostate Cancer drug this draws more than 2 billion in retch, proceeds that are split with the partner. And it gains two experimental drugs for cancer, building up a growing fo global spending on cancer medicines reached 107 billion la...

Sanofi made an overture, and have astrazeneca, celgene and gilead, but it was pfizers 14 billion that won out. Sending shares up almost 20 . Shares of pfizer fell slightly. Meg tirrell tells us why medivation was so sought after. Reporter a 14 billion deal phaser beat our rivals to win in an allcash deal that capped a monthlong process. With it pfizer gained the Prostate Cancer drug this draws more than 2 billion in retch, proceeds that are split with the partner. And it gains two experimental drugs for cancer, building up a growing fo global spending on cancer medicines reached 107 billion la...